Spyre Therapeutics Announces Proposed Public Offering of its Common Stock

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

• Spyre's pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, and IL-23

  60% confidence

• The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering

  60% confidence

• The Company aims to create the next-generation of inflammatory bowel disease (IBD) and other immune-mediated disease products by combining best-in-class antibody engineering, dose optimization, and rational therapeutic combinations

  60% confidence

• The Company is expected to grant the underwriters of the offering an option for a period of 30 days to purchase an additional $45.0 million of shares of common stock at the public offering price, less the underwriting discount

  60% confidence

Cited in these Via News reports

• FDA Fast-Tracks Lung Cancer Drug as Biotech Sector Logs $430M in Deals →